v3.25.3

Statements of Cash Flows (Unaudited) - USD ($)	9 Months Ended
Statements of Cash Flows (Unaudited) - USD ($)	Sep. 30, 2025	Sep. 30, 2024
Operating activities:
Net loss	$ (11,435,485)	$ (7,748,590)
Adjustments required to reconcile net loss to net cash used in operating activities:
Amortization	1,779	2,709
Stock-based compensation	4,632,642	1,783,566
Changes in operating assets and liabilities:
Accounts payable	(68,650)	518,442
Unreimbursed expenses – related party (accrued)	130,918	29,536
Net cash used in operating activities	(6,738,796)	(5,414,337)
Financing activities:
Sale of common stock via ATM program, net of costs	6,308,784	1,747,282
Net proceeds from exercise of remaining underwriter warrants	145,000
Sale of common stock via Private Placement, net of costs		2,499,998
Net cash provided by (used in) financing activities	6,453,784	4,247,280
Net increase (decrease) in cash	(285,012)	(1,167,057)
Cash, beginning of period	4,091,990	6,989,424
Cash, end of period	$ 3,806,978	$ 5,822,367

The aggregate amount of recurring noncash expense charged against earnings in the period to allocate the cost of assets over their estimated remaining economic lives.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Section 45
-Paragraph 28
-Subparagraph (b)
-SubTopic 10
-Topic 230
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482740/230-10-45-28

Greenwich LifeSciences, Inc. 10-Q